Table 2.
Ongoing clinical trials assessing the efficacy of baricitinib in conditions other than rheumatoid arthritis (last search, September 2018)
| Clinical trial number | Methodology | Comparison | Indication | Estimated study completion date |
|---|---|---|---|---|
|
| ||||
| NCT03616964 | RCT, Phase III, double blind | Baricitinib vs placebo | Systemic lupus erythematosus | February 2021 |
| NCT03616912 | RCT, Phase III, double blind | Baricitinib vs placebo | Systemic lupus erythematosus | February 2021 |
| NCT03334422 | RCT, Phase III, double blind | Baricitinib vs placebo | Atopic dermatitis (moderate to severe) | January 2019 |
| NCT03559270 | Single arm, Phase III, open label | Baricitinib | Atopic dermatitis (moderate to severe) | May 2021 |
| NCT03334435 | RCT, Phase III, double blind | Baricitinib vs placebo | Atopic dermatitis | August 2021 |
| NCT03334396 | RCT, Phase III, double blind | Baricitinib vs placebo | Atopic dermatitis (moderate to severe) | August 2019 |
| NCT03435081 | RCT, Phase III, double blind | Baricitinib vs placebo | Atopic dermatitis (moderate to severe) | January 2021 |
| NCT03428100 | RCT, Phase II and III, double blind | Baricitinib vs placebo (both in combination with topical corticosteroids) | Atopic dermatitis (moderate to severe) | March 2021 |
| NCT03570749 | RCT, Phase II and III, double blind | Baricitinib vs placebo | Severe or very severe alopecia areata | July 2022 |
| NCT03026504 | Single arm, Phase II, open label | Baricitinib | Giant cell arteritis | June 2021 |
| NCT02759731 | Single arm, Phase I and II, open label | Baricitinib | Chronic graft-vs-host disease after allogenic hematopoietic stem cell transplantation | June 2020 |
Abbreviation: RCT, randomized controlled trial.